news
Thomson Reuters names most promising drugs of 2015
24 March 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report...
List view / Grid view
Novartis
news
Novartis receives EU approval for Jakavi ®, the first targeted therapy approved for patients with the rare blood cancer polycythemia vera
18 March 2015 | By Victoria White
Novartis announce that the EU has approved Jakavi ® for the treatment of adult patients with polycythemia vera (PV)...
news
Novartis to present new late-breaking Cosentyx data at AAD 2015 showing significant patient benefit in achieving clear skin
13 March 2015 | By Novartis
Novartis announced that new results for Cosentyx(TM) (secukinumab) in moderate-to-severe plaque psoriasis, including detailed findings from the head-to-head CLEAR study and long-term data from the Phase III program, will be presented as late breaking research at the 73rd Annual Meeting of American Academy of Dermatology...
news
Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib
27 February 2015 | By Novartis
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Zykadia® (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib...
news
Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera
23 January 2015 | By Novartis
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea...
news
Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®
8 December 2014 | By Novartis
Sandoz, a Novartis company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's NEUPOGEN ® (filgrastim) in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy...
news
Future bleak for Novartis’ Panobinostat in relapsed/refractory multiple myeloma, says GlobalData analyst
21 November 2014 | By GlobalData
The vote against the recommendation that the US Food and Drug Administration (FDA) approves Novartis’ panobinostat (Farydak) for use in relapsed/refractory multiple myeloma by the Oncologic Drugs Advisory Committee (ODAC) signals that a US marketing authorization is unlikely to be granted, according to an analyst with research and consulting firm…
news
Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One
12 November 2014 | By Novartis
Novartis announced that, through Power of One, enough funds have been raised to deliver three million antimalarial treatments for children in Zambia...
news
Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb’s novel immunotherapy in combination treatments for NSCLC
6 October 2014 | By Novartis
Novartis announced that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor...
news
Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression
10 September 2014 | By Novartis
Novartis announced that new data presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA, reinforces the clinical importance of measuring brain shrinkage (brain volume loss) in multiple sclerosis...
news
Gilenya® data at ACTRIMS-ECTRIMS to show Novartis is redefining MS treatment goals for patients
3 September 2014 | By Novartis
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA from September 10-13, 2014...
news
Novartis provides drug candidate compounds to TB Alliance
20 August 2014 | By Novartis
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development for compounds to fight tuberculosis that have been discovered at the Novartis Institutes for Tropical Diseases...
news
Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
11 August 2014 | By Novartis
New data revealing the reduction in cardiovascular deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest cardiology congress...
news
Alcon’s Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease
4 August 2014 | By Novartis
Alcon announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission to decrease elevated intraocular pressure...
news
KAE609 shows promise as next generation treatment for malaria
31 July 2014 | By Novartis
Novartis published clinical trial results in the New England Journal of Medicine showing that KAE609 (cipargamin), a novel and potent antimalarial drug candidate...
